Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
比较度伐利尤单抗、奥拉帕尼和西地尼布单药治疗、联合治疗或化疗治疗既往接受过贝伐珠单抗治疗的铂耐药卵巢癌患者的疗效：II期NRG-GY023试验
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-3877
Lee, Jung-Min; Miller, Austin; Rose, Peter G; AlHilli, Mariam; Washington, Christina; John, Veena S; Shah, Chirag A; Matsuo, Koji; Siedel, Jean; Miller, David S; Hopp, Elizabeth E; O'Shea, Andrea; Chan, John K; Bradford, Leslie S; Morse, Christopher B; Nagel, Christa I; Rodabaugh, Kerry J; Kohn, Elise C; Moore, Kathleen N; Liu, Joyce F
